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ABSTRACT 
 
Experimental allergic encephalomyelitis (EAE) is considered as the murine model of multiple 
sclerosis. Daidzein a phytostrogenic compound of soy is known to impose immunomodulatory and 
antioxidative effects. We conducted this study to assess the potential protective and therapeutic 
effects of daidzein on allergic encephalomyelitis.  
C57BL/6 mice were induced with allergic encephalomyelitis using myelin oligodendrocyte 
glycoprotein (35-55) and received daidzein or dimethyl sulfoxide as the vehicle control. To assess 
the protective effect of daidzein, the mice were administered with 20 mg/kg of daidzein from 21 
days prior to 21 days post EAE induction on a daily basis. To evaluate the therapeutic effect of 
daidzein, mice were fed with 300 mg/kg daidzein after the appearance of the first clinical signs for 
10 days. One day after the last gavage, the mice were sacrificed. Spleen and brain were removed for 
further histological and immunological analysis.  
Feeding mice with low dose of daidzein prior to disease induction did not affect disease severity. 
However, treating with high dose of daidzein after the onset of the disease reduced interferon-γ and 
interleukin-12 secretion, enhanced interleukin-10 production, suppressed lymphocyte proliferation, 
and decreased cytotoxicity as judged by lactate dehydrogenase release. 
In conclusion, daidzein reduced the extent of demyelination and disease severity. Chronic oral 
therapy with low dose of daidzein did not prevent experimental autoimmune encephalomyelitis. 
However, high doses of daidzein could prohibit disease exacerbation.  
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INTRODUCTION 
 
Multiple sclerosis (MS) is an immune-mediated 
inflammatory disease of the central nervous system 
(CNS) that can lead to irreversible clinical disability in 
most severe cases.1 Most of the current approved 
therapies possess some disadvantages that can cause 
non-adherence to treatment including administration via 
injection, costs, partial effect, and potential toxicity.2 
Moreover, although current therapies are effective at 
decreasing the frequency and severity of relapses, they 
have little impact on progressive forms of the disease. 
Experimental allergic encephalomyelitis (EAE) is a T-
cell mediated autoimmune disease, validated as the 
animal model of MS.3 Both CD4+ and CD8+ T-cells 
were reported to be important in the development of 
EAE.4 In EAE many T helper (Th)1-type cytokines 
(proinflammatory) contribute to the process of 
demyelination, while several Th2-type cytokines have 
been implicated in remyelination and survival of 
neurons.5 
Daidzein is one of the most potent isoflavones of soy 
bean. Soy bean is known as the main dietary source  
of isoflavones and has been traditionally consumed  
in Far East countries.6 Isoflavones, as a group of 
phytoestrogens, appeared to possess weak estrogenic 
and/or antiestrogenic actions.7 Considering the 
immunomodulatory actions of estrogen, it may be 
probable that daidzein also influence the immune 
system. A study, treating ovariectomized balb/c mice 
with daidzein resulted in a reduction of splenic CD4+ T 
cells and tumor necrosis factor-alpha (TNF-α) 
secretion.8 Daidzein was also reported to suppress 
Interferon-gamma (IFN-γ) production in splenocytes 
isolated from C57BL/6 mice.9 Treating mice with 20 
mg/kg of daidzein was also reported to reduce plasma 
levels of Interleukine (IL)-6 and TNF-α in an animal 
model of rheumatoid arthritis.10 In addition daidzein  
is known to possess antioxidative properties.11 
Moreover, intraperitoneal injection of 200 mg/kg of 
genistein, another soy isoflavone, to EAE-induced 
C57BL/6 mice has recently been reported to modify 
Th1/Th2 balance and reduce rolling and adhering  
of leukocytes.12,13 Regarding the structural similarity  
of genistein and daidzein and the immunomodulatory 
and antioxidative roles of daidzein, we conducted this 
study to investigate potential protective and therapeutic 
effects of oral daidzein on the progressive model of 
EAE.  
MATERIALS AND METHODS 
 
Mice 
The study was performed on 10-12 week old female 
C57BL/6 mice (Pasture institute, Iran). The animals 
were housed with free access to food and water on a 12 
hour light-dark cycle. All protocols used in this 
experiment were approved by the Tehran University of 
Medical Sciences committee on laboratory animals. The 
mice were assigned into four groups, two groups in each 
set of experiments. In the first set of the experiment, the 
protective effect of oral daidzein was studied. In second 
set, the therapeutic effect of daidzein was the subject of 
the study.  
 
Daidzein Administration  
To assess the protective effect of daidzein, the mice 
(n=6/group) were: 1) administered with 20 mg/kg 
daidzein dissolved in 0.1 ml of Dimethyl sulfoxide 
(DMSO, Sigma Aldrich, USA) (11%) (daidzein-
protection), 2) gavaged with 0.1 ml DMSO 11% as the 
vehicle control (n= 6/group) (control-protection). Oral 
gavage began 21 days before immunization and 
continued up to 21 days after immunization on daily 
bases (43 days including day 0). Twenty mg/kg of 
daidzein has been reported to have immunomodulatory 
effects in collagen induced arthritis (CIA) and 
consequently protect rats against this autoimmune 
disease.10 As CIA and EAE have similar pathology, we 
adopted this dose for assessing the protective potency of 
daidzein. 
To study the therapeutic effect of daidzein, the mice 
were induced with EAE. After the appearance of the 
first clinical sign (score=1), the mice were administered 
with 1) 300 mg/kg daidzein dissolved in 0.1 ml DMSO 
11% (daidzein-therapy), or 2) 0.1 ml DMSO as vehicle 
control (control-therapy).   As the bioavailability of oral 
daidzein is about 50%, for assessing the therapeutic 
effect of daidzein, we administered mice with 300 
mg/kg of daidzein.14 
 
EAE Induction 
The mice were immunized with a 1:1 ratio of myelin 
oligodendrocyte glycoprotein (MOG) 35-55 (Alexis, 
Switzerland) dissolved in Phosphate buffered saline 
(PBS) (300 µg MOG in 100 µL PBS) and complete 
Freund’s adjuvant (CFA) (100 µL) containing 0.4 mg of 
mycobacterium tuberculosis (Sigma-Aldrich, USA). In 
the first set of the experiments, after 21 days of gavage, 
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200 µL/ mouse MOG-CFA emulsion was 
subcutaneously administered on the four sites of  
the upper flanks (day 0). The additional immune 
adjuvant, pertussis toxin (PTX) (Sigma-Aldrich, USA) 
in 10% PBS was intraperitoneally injected (500 
ng/mouse) on the initial day of immunization and again 
48 hours later. In the second set of the experiments,  
after a week of adaptation, the EAE was induced in mice 
by protocol. 
 
Clinical Evaluation of EAE 
The following grading scheme was used to clinically 
score the animals: 0, for no clinical signs, 0.5, hook tail, 
1, flaccid/floppy tail, 2, walking deficits, 2.5, unilateral 
hind limb paralysis 3, bilateral hind limb paralysis, 3.5, 
paraplegia with forelimb weakness, 4, quadriplegia and 
5, for moribund.  
In the first set of the experiments, the clinical scores 
were assessed daily for 21 days post immunization. In 
the second set of the experiments, clinical scores were 
assessed daily up to 10 days after the appearance of  the 
first clinical sign.  
 
Histological Assessments 
Twenty-four hours after the last treatment, the mice 
were sacrificed. Brain of the animals were removed and 
post-fixed in 10% paraformaldehyde and stored at 4O C 
for 48 hours. Prior to sectioning, the tissues were put in 
PBS 10% for 24 h and imbedded in paraffin. The brain 
sections (8 microns) were cut on the cryostat and 
stained. For assessing the percentage of demyelination 
luxol fast blue- LFB (Merck, Germany)/ Cresyl fast 
violet (BDH, England) staining was used. 
Demyelination was assessed in at least 5 sections for 
each mouse. 
 
Spleen Cytokine Assessment   
The mice were sacrificed 24 hours after the last 
gavage and their splenocytes were isolated. 
Mononuclear cells obtained from spleens of the 
immunized mice were prepared and incubated with 1.5 
ml in RPMI-1640 medium at a concentration of 2×106 
cells/well in 24-well plate (Nunc, Denmark) for two 
days. The RPMI was supplemented with 10% FCS, 1% 
L-glutamine, 1% HEPES, 0.1% 2ME, and 0.1% 
penicillin/streptomycin, and pulsed with 10µg/ml 
daidzein. The cell supernatants were collected. The 
amount of cytokines (INF-γ, IL-10 and IL-12) in cell 
supernatants was assessed using sandwich-based ELISA 
kits (ELISA Ready-SET-Go, eBioscience, USA). The 
tests were performed according to the manufacturer’s 
protocol. All tests were performed in triplicate for each 
mouse.  
 
Brain Cytokine Assessment 
The concentration of brain cytokines (INF-γ, IL-10 
and IL-12) was assessed 24 hours after the last gavage. 
For this purpose, 100 mg of the brain tissue of each 
mouse was dissolved in 10 ml of extracting solution 
consisting of 50 µM tris (Sigma-Aldrich, USA), 2 mM 
EDTA (Merck, Germany), 0.1 M NaCl (Sigma-Aldrich, 
USA), 1 mM dithiotheritol (Merck, Germany), and 200 
µM phenylmethylsulfonyl fluid (Merck, Germany), 1 
µg/ml chymostatin (Sigma-Aldrich, USA), and 1 µg/ml 
trypsin inhibitor (Sigma-Aldrich, USA) (15) . Brain 
homogenate was spun at 4oC for 10 minutes at 10000 g. 
Level of INF-γ, IL-12 and IL-10 were determined in 
brain supernatant using sandwich-base ELISA kit 
(eBioscience, USA) following the manufacturer’s 
instruction. All tests were performed in triplicate for 
each mouse. 
 
Lymphocyte Proliferation Assay (LPA) 
Twenty four hours after the last oral administration, 
single cell suspension of mononuclear cells  
was obtained from the immunized mice and used  
for lymphocyte proliferation assay. Briefly, the 
suspension of isolated spleen cells was treated with  
lysis buffer [0.15 M NH4Cl, 1 mM KHCO3, 0.1  
mM Na2EDTA, (pH 7.2)]. In 96-well flat-bottom 
culture plates (Nunc, Denmark), 2x105 cells/ well  
were cultured. The preparations were cultured with 
RPMI-1640 medium supplemented with 10% fetal  
calf serum, 1% L-glutamine, 1% HEPES, 0.1% 2ME, 
0.1% penicillin/streptomycin and incubated in the 
presence of 10 µg/ml daidzein. T cell mitogen 
phytohemagglutinin-PHA (Sigma chemicals, Australia) 
at a concentration of 5 µg/ml was used as the positive 
control. After 3 days, MTT (3-(4, 5-Dimethylthiazol-2-
yl)-2,5-Diphenyltetrazolium Bromide) (Sigma 
chemicals, Australia) was added per well in 
concentration of 5 µg/ml and was incubated for 5 hours 
at 37 ºC in 5% CO2. DMSO (100 µl) was added to 
dissolve the produced formazan crystals. 
The plates were read at 540 nm, and the results were 
expressed as stimulation index (SI). The SI was 
determined as follows: OD values of stimulated cells 
(Cs) minus relative cell numbers of unstimulated cells 
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(Cu) by relative OD values of unstimulated cells. 
SI = (Cs _ Cu)/Cu 
All tests were performed in triplicate for each 
mouse.-16 
 
Cell Cytotoxicity Assay 
Twenty-four hours after the final administration, the 
mice were sacrificed and their splenocytes were isolated. 
For each sample obtained from an individual mouse, 
single cell suspension of mononuclear cells (used as the 
effecter cells) was co-cultured in RPMI 1640 medium 
with washed target cells, EL4 at various effector-to-
target cell for 4 h in phenol red-free RPMI 1640 
containing 3% FCS. For preparation of the target cells, 
EL-4 cells were stimulated with daidzein antigen.  
After centrifugation, the supernatants (50 µl/ well) 
were transferred to the 96-well flat-bottom plates, and 
lyses of the target cells were determined by measuring 
Lactate dehydrogenase (LDH) release using 
Cytotoxicity Detection Kit (LDH) according to the 
procedures stated by the manufacturer (Takara 
Company, Japan). Several controls were used for the 
cytotoxicity assay. 
“High control” was the total LDH released from the 
target cells, and all EL4 cells were lysed by a medium 
containing 1% Triton X-100. “Low control” was the 
natural release of LDH from the target cells, which was 
obtained by adding EL4 cells only in the assay medium. 
“T-cell control” was used to measure the natural release 
of LDH from T cells obtained by adding different ratios 
of T cells only in the assay medium. The assay was 
performed in triplicates for all samples, including the 
controls. 
The LDH-mediated conversion of the tetrazolium 
salt into red formazan product was measured at 490 nm 
after incubation at room temperature for 30 min. The 
percentage of specific cytolysis was determined by the 
following formula: 
% Cytotoxicity 
 
experimental value  effector cell control
 low control high control  low control⁄   100 
 
Statistical Analysis 
The data were analyzed with SPSS 17. One-way 
analysis of variances (ANOVA) was used to compare 
clinical and histological signs of the disease, as well as, 
cytokine concentrations between the studied groups. 
Sheff’s honesty significant intergroup comparison at the 
0.05 level of significance was adopted for all 
comparisons. 
 
RESULTS 
 
Clinical Assay 
In the first set of the experiments, daidzein 
administration (20 mg/kg) did not prevent mice from 
EAE. The low dose of daidzein did not significantly 
affect the day of onset, mean daily, commutative, or 
maximum clinical score (Figure 1). 
In the second set of the experiments, the mice were 
gavaged with dadizein or DMSO up to 10 days after the 
appearance of the first clinical sign. 9 to 14 days 
following immunization, mice developed clinical signs 
of EAE. No significant differences in the mean onset 
time were observed between the two groups. The mean 
daily clinical score of the daidzein-treated group was 
always lower than the controls; the differences became 
significant on days 17, 18, and 19. Daidzein also 
significantly reduced cumulative and maximum disease 
score (Figure 1 and Table 2). 
In the first set of the experiments, demyelinated 
lesions were scattered widely throughout the brain in 
DMSO-treated mice. The daidzein-treated mice did not 
show milder CNS pathology compared to controls. In 
the second set of the experiments, demyelination was 
notably absent in the daidzein treated mice (Figure 2). 
 
Table 1: Effect of oral administration of daidzein or DMSO on clinical signs of experimental allergic encephalomyelitis (EAE) 
  Incidence‡ Onset (day) Commutative 
disease score 
Maximum clinical score 
Protection Control 6/6 11.33±1.5 25.25±7.99 3±0.45 
Daidzein 5/6 11.25±0.51 22.25±3.88 2.87±0.62 
Therapy Control 5/6 11±1.67 23.25±5.33 2.91±0.37 
 
Daidzein 6/6 11.2±1.6 12.5±5.67* 1.6±0.82* 
The mega-dose of daidzein (300 mg/kg) decreased commutative and maximum disease score significantly. All data is represented as 
mean± SD. ‡ratio, *P<0.05 compared to control-therapy 
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Figure 1. Effects of oral administration of daidzein on the mean daily clinical scores of experimental allergic 
encephalomyelitis (EAE). Administering with 20 mg/kg (n=6) from 21 days prior to 21 days post immunization did not reduce 
the severity of clinical signs compared to the vehicle controls. Gavaging with daidzein after the onset of clinical signs for 10 
days reduced the mean daily clinical score. The difference became significant (p<0.05) from day 17 to 19 compared to control 
group.. All data is represented as mean± SD.  
 
 
 
A-1        A-2 
 
B-1        B-2 
Figure 2. Demyelination of the brain. A, brain sections of control-protection (A-1), daidzein-protection (A-2), control-therapy 
(B-1), and daidzein-therapy (B-2) groups are stained using luxol fast blue & Cresyl fast violet. 20 mg/kg of daidzein was used 
as a protective dose from 21 days prior to 21 days post induction. 300 mg/kg of daidzein was used as a therapeutic dose for 10 
days after disease onset. Therapeutic dose of daidzein reduced the extent of demyelination.  
 
47 μm 
49  μm 
62 μm 
46.1 μm 
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Immunological Assay  
Cytokine Profile 
The animals were sacrificed 24 hours after the last 
treatment. In the first set of the experiments, brains and 
spleens of the animals were dissected. In splenocytes 
isolated from daidzein-treated animals after daidzein 
exposure, no significant differences were detected in 
levels of IFN-γ, IL-12, and IL-10. The comparable effect 
was noted on brain cytokine profile (Figure 3). 
As presented in figure 3, in the second set of  
the experiments, in the splenocytes removed from 
daidzein-treated group, after daidzein exposure, IFN-γ  
and IL-12 levels were significantly down regulated 
compared to vehicle-control (p=0.02 and 0.002, 
respectively). Daidzein also reduced IFN-γ (p=0.024) 
secretion in brain.  It enhanced IL-10 secretion in  
brain and splenocytes (p= 0.014 and 0.001, 
respectively).   
 
 
 
  
   
Figure 3. The effect of daidzein on cytokine profile (IFN-γ, IL-10 and IL-12) of spleen and brain. To assess the protective role 
of daidzein, the mice either received daidzein (20 mg/kg) or DMSO as the vehicle control from 21 days before to 21 days after 
immunization. To evaluate the therapeutic effect of daidzein, mice were either gavaged with daidzein (300 mg/kg) or DMSO 
after the onset of clinical signs for 10 days.  Treating mice with daidzein after the onset of the disease notably reduced IFN-γ 
level in brain and splenocytes. It also significantly decreased IL-12 level in splenocyte. Moreover, therapeutic dose of daidzein 
enhanced IL-10 secretion in brain and splenocytes. All data are represented as mean± SD. *P<0.05, **P<0.005. †ng/dl 
**
  
**
*
**
  
† † 
*
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Lymphocyte Proliferation   
Proliferative response of splenocytes’ lymphocytes 
was assessed using MTT test. In the first set of  
the experiments, in the immunized mice with  
daidzein, the proliferative response of lymphocytes  
was suppressed, but the difference was not significant  
in comparison to the control group. In the second  
set of the experiments, the stimulation  
index of lymphocytes was reduced significantly (Figure 
4).  
 
LDH Cell Cytotoxicity  
Twenty-four hours after the final treatment, single 
cell suspension of mononuclear cells (effecter cells) was 
co-cultured with pulsed EL-4 cells (target cell). 
As shown in Figure 5, in lymphocytes of mice  
that received the therapeutic dose of daidzein, specific 
cytolytic activity was suppressed at an E/T ratio of  
50:1 significantly as compared to that of DMSO-treated 
animals (25.2±2.8% v.s. 33.7±1.09%) group. The most 
significant differences between all studied groups were 
at 50:1 E/T ratios (Figure 5). 
 
 
 
 
Figure 4. Lymphocyte proliferation evaluation, using  
MTT assay. Lymphocyte proliferation response was 
measured in daidzein-treated (20 mg/kg or 300 mg/kg) 
mice and compared with DMSO-treated animals. In mice 
treated with the therapeutic dose of daidzein, lymphocyte 
proliferation response was significantly lower, in 
comparison to the DMSO group. All data are expressed as 
mean± SD. *P<0.05. 
 
 
Figure 5. Cell cytotoxicity assays in mice treated with 
daidzein using LDH release assay. After oral treatment 
with DMSO or daidzein (20 mg/kg from 21 days before 
EAE induction or 300 mg/kg after disease onset), the 
spleens were harvested as described in materials and 
methods.  The data were collected from LDH results at 
various E/T ratios (E/T=25:1, 50:1, 100:1) and expressed as 
cytotoxicity percentage ± SD. The data shown here are 
from three independent experiments with triplicates. The 
percent of cytotoxicity was significantly lower in the 
daidzein-treated group compared to vehicle-control. 
*P<0.05 compared to control. 
 
DISCUSSION 
 
Few evidences exist on the immunomodulatory 
effect of daidzein. Up to the best of our knowledge, no 
study has previously been performed on the effect of 
daidzein on EAE. We found that administrating mice 
with high doses of daidzein after the onset of the disease 
can attenuate EAE severity.  However, gavaging with a 
low dose of daidzein prior to EAE-induction does not 
provide protection against disease induction.  
The therapeutic dose of daidzein reduced the 
stimulation index of lymphocytes which mainly 
represents memory CD4+ T-cell proliferation. High dose 
of daidzein also decreased the percent of cytotoxicity 
which mainly manifested CD8+ activity. EAE is mainly 
characterized by infiltration of myelin-auto reactive 
CD4+ and CD8+ T cells into the CNS.16 We also 
showed that gavaging with high dose of oral daidzein 
resulted in suppression of IFN-γ and IL-12 production, 
as well as the enhancement of  IL-10 secretion. IFN-γ 
also controls the differentiation of CD4+ cells into Th1 
effectors as well as, initiating the production of pro-
inflammatory cytokines.17 IFN-γ was found to be 
*
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increased in the CSF and CNS of patients with MS and 
IFN-γ administration to MS patients exacerbates the 
disease.18 IL-10 is an anti-inflammatory cytokine that is 
produced by macrophages, monocytes, B cells and Th2 
cells. It inhibits the production of pro-inflammatory 
Cytokines (IL-1 and TNF-α) by macrophages.19 In EAE 
models, mice with IL-10 deficiency developed more 
severe EAE compared to the controls and even to IL-4 
deficient mice, suggesting IL-10 has a unique role that 
cannot be substituted by other Th2 cytokines.20 
Treatment with IL-10 has also been shown to protect 
against EAE progression in mice.20 
In agreement with our results, a previous in vitro 
study reported that high doses of daidzein (50 µm) 
reduced IFN-γ production and lymphocyte proliferation 
of concanavalin A-stimulated splenocytes.21 Also, Tyagi 
AM. et al. reported that gavaging ovariectomized Balb/c 
mice with daidzein reversed the ovariectomy induced 
CD4+ T cell expression in spleen.8 As mentioned 
previously, De paula et al. reported that intraperitoneal 
administration of 200 mg/kg genistein, after the onset of 
disease, reduced EAE severity by reducing IFN-γ and 
IL-12 production, decreasing the rolling and adhering of 
leukocytes on brain microvasculature, as well as 
enhancing IL-10 secretion.12 Our results showed that 
similar to genistein, therapeutic dose of daidzein can 
attenuate EAE severity.     
Few in vivo studies were performed on the 
immunomodulatory effects of daidzein. One of the best 
examples was a study on CIA. Mohammad-Shahi  et al. 
reported that treating CIA-induced Spraugue-Dawley 
rats with 20 mg/kg daidzein postponed disease onset and 
reduced its severity.10 Also in an in vitro study, 10 -8 M 
daidzein reduced IFN-γ production in splenocytes 
isolated from C57BL-6 mice.9 In contrast to 
Mohammad-shahi results and the previous in vitro 
study, in our study low-dose daidzein did not show the 
predicted protective effect on EAE. The observed 
difference with the previous in vivo study may be due to 
the difference in the pathological feature of EAE and 
CIA. They reported that the low dose of daidzein protect 
rats against CIA by reducing the serum concentration of 
TNF-α, IL-6, and leptin. Ideas on the role of IL-6 in 
EAE are controversial. IL-6 signaling has been 
identified as a stimulant that directs cells toward Th17. 
In a number of recent studies, Th17 (IL-17A-secreting-
Th cells) was considered essential in developing EAE. 
On the other hand, in another study greatly increased 
levels of T cell-derived IL-17A expression was reported 
to have no effect on the development of EAE and the 
quality and quantity of CNS inflammation.22 TNF-α was 
also playing a dual role during EAE. The complete 
elimination of TNF-α may induce disease severity. 
However, incomplete modulation of TNF-α expression 
may provide protection against EAE.23 So reducing IL-6 
and TNF-α level might not necessarily induce tolerance 
to EAE. A major difference between our in vivo animal 
study and the previous in vitro study was the 
bioavailability of daidzein that could have been 
significantly influenced the results. Furthermore, 
physiological and pathological factors in autoimmune 
disease including other immune cells may play a role in 
predicting lymphocyte potentiation and cytokine action. 
 To mention our limitations, we did not evaluate the 
activity of CD4+ and CD8+ T cells with more elaborate 
methods. However, we cannot rule out daidzein effect 
on CD4+ and CD8+ T cells measured by MTT and LDH 
tests. Further studies on protective and therapeutic 
effects of different doses of daidzein are warranted. 
In conclusion, Oral administration of low dose of 
daidzein did not prevent EAE progression. However, 
treating with high dose of daidzein at the onset of 
clinical signs modulated T-cell response and 
consequently alleviated disease symptoms.  
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